Foscarnet nephrotoxicity: mechanism, incidence and prevention. - Wikidata - awgldk - TriplyDB

Foscarnet nephrotoxicity: mechanism, incidence and prevention.

Foscarnet nephrotoxicity: mechanism, incidence and prevention.

http://www.wikidata.org/entity/Q42188852

about

Antiviral drug resistance: mechanisms and clinical implications Nonnucleoside pyrrolopyrimidines with a unique mechanism of action against human cytomegalovirus Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance Irreversible glomerular lesions induced by crystal precipitation in a renal transplant after foscarnet therapy for cytomegalovirus infection Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27 Medical and virological aspects of ocular human immunodeficiency virus infection for the ophthalmologist.Long term renal survival in patients undergoing T-Cell depleted versus conventional hematopoietic stem cell transplants.Nucleotide analogs related to acyclovir and ganciclovir are effective against murine cytomegalovirus infections in BALB/c and severe combined immunodeficient mice Drug-induced impairment of renal function.Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet.Foscarnet alters antidiuretic hormone-mediated transport.Potent anti-murine cytomegalovirus activity and reduced nephrotoxicity of ganciclovir cyclic phosphonate.Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS.The use of antiviral drugs during the neonatal period Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.Emerging therapies for herpes viral infections (types 1 - 8).Antiviral therapy: current concepts and practices Brincidofovir Use after Foscarnet Crystal Nephropathy in a Kidney Transplant Recipient with Multiresistant Cytomegalovirus Infection.Drug-induced glomerulopathies.Role of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribonucleosides.Inhibition of cyclooxygenase activity blocks cell-to-cell spread of human cytomegalovirus Human herpesvirus 6 infections after liver transplantation Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms.Drug-induced acid-base disorders.Cytomegalovirus prophylaxis and treatment following bone marrow transplantation.Management of CMV retinitis in HIV infected patients.A double-blind placebo-controlled crossover trial of intravenous magnesium sulfate for foscarnet-induced ionized hypocalcemia and hypomagnesemia in patients with AIDS and cytomegalovirus infection.Isolation and identification of compounds from Kalanchoe pinnata having human alphaherpesvirus and vaccinia virus antiviral activity.Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.Cytomegalovirus retinitis in persons with AIDS.The anti-human cytomegalovirus drug tricin inhibits cyclin-dependent kinase 9.The Prevention and Management of Contrast-induced Acute Kidney Injury: A Mini-review of the Literature

P2860

Q28282376-84D20CBB-87B9-4E1F-AE0C-2143522F3E73 Q28343467-DCF3F96A-CF5F-4207-993A-FF73519F4281 Q28365182-51DBCA02-1F45-4831-8370-DD13AF0BFA79 Q28374909-3D41DC26-7877-45A6-B6CB-A7B798EE1D10 Q31011523-76DBD884-2EB7-418E-882B-38173DD739A0 Q33569593-687190E2-E2F6-43A0-BE70-60D222A57696 Q33633514-3591F7F2-A0E6-45D6-933F-201E2D856453 Q33759331-27D62811-5718-4D0E-BECD-129E7CBD02E7 Q34731462-BD573462-FD4F-4C55-9744-A57F27BBA306 Q35118174-84594C76-596C-4E78-A6E9-287721F34806 Q35118306-FBE4A9FC-2A2A-4BCE-9301-BCDF14F3232F Q35126399-82B988DA-E639-42F8-AA9A-53A0B07ABBA0 Q35136484-6E593014-6920-4586-8D90-878B6A8F27EA Q35789702-40C25DCA-E9A5-4D37-9E17-1B6467975E87 Q35821073-EF123601-C875-43C8-98BE-D3B861671211 Q35896783-68D6451F-7EB3-4A18-88E8-82E896B074E1 Q35967376-93C8A0A7-0BCE-4AAB-BD2A-911753B0D185 Q36070394-1D584F49-1149-4D0C-8552-648736C20D83 Q36324846-B355EFBB-E803-48FF-A5A8-B1F849481EE2 Q36349741-E6F055D4-7BC0-4376-896B-4A434F31E1AD Q36944070-3A5F9C54-B21D-413F-AE99-C37F8070DC74 Q37039604-4B3072D8-4FA5-4879-A3FB-1F3326BCFD3D Q37507814-0FB1B4C7-385B-4129-86C6-A08E52B70FDD Q37568962-94E89A41-81F1-4868-B6FD-E41B6EF358AB Q38265082-475A7FBF-83BF-4CAD-951D-49C53977A8A3 Q38560786-5CEDF30E-C74E-498D-8BF8-14F56D7AE3D6 Q39123462-998B6E01-8A57-475A-BB8E-59F2E3D30279 Q39474633-CB30D74A-25C6-4B58-83AA-ECB6E7028A44 Q40249810-07D71A0B-4296-4091-8F47-17DF571C51C6 Q40883043-360518D8-5DAB-4A6D-8224-5DB7FF064B7D Q50008558-29A741D7-0505-42CC-9630-0A40BEECCF1C Q53831437-76A6BA45-8FB6-47FE-BEB8-9E07805EF261 Q59132622-FE21B349-FF56-4A1A-8A01-172D23AF3A3F

P2860

Foscarnet nephrotoxicity: mechanism, incidence and prevention.

http://www.wikidata.org/entity/Q42188852

description

1989 nî lūn-bûn

@nan

1989年の論文

@ja

1989年学术文章

@wuu

1989年学术文章

@zh-cn

1989年学术文章

@zh-hans

1989年学术文章

@zh-my

1989年学术文章

@zh-sg

1989年學術文章

@yue

1989年學術文章

@zh

1989年學術文章

@zh-hant

name

Foscarnet nephrotoxicity: mechanism, incidence and prevention.

@en

Foscarnet nephrotoxicity: mechanism, incidence and prevention.

@nl

type

label

Foscarnet nephrotoxicity: mechanism, incidence and prevention.

@en

Foscarnet nephrotoxicity: mechanism, incidence and prevention.

@nl

prefLabel

Foscarnet nephrotoxicity: mechanism, incidence and prevention.

@en

Foscarnet nephrotoxicity: mechanism, incidence and prevention.

@nl

P1433

Q42188852-72A7D971-61CC-4247-8A09-7E4C29ADB99B

P1476

Q42188852-E19FC3DA-D821-4658-8224-C5F1DE1AF89A

P2093

Q42188852-018C49D9-4AC9-415B-8EAC-3D7FAE03189E

Q42188852-18736F24-8921-4F0E-97D7-A9175747E6FA

Q42188852-319F859F-3710-4BA8-908D-23FD618A8135

Q42188852-3238B968-1C0F-430D-BDFF-851F4983D8B1

Q42188852-54E91F16-FCE5-4BE6-8B06-E36714E80B8D

Q42188852-80CE0A70-D2C6-488A-AC75-8CCAC21B990A

Q42188852-850CFA91-4498-4B8D-90F9-8EF40454D652

Q42188852-D000A15E-430C-4601-9AE4-57242CEF2CD9

Q42188852-FB886935-016A-49D9-BCC3-B3AFCE9D8D9D

Q42188852-FC84FFB7-3DF3-4C23-9B6B-82E819996AA5

P304

Q42188852-D0F67AC6-B4E5-42D8-84D1-504372D8A826

P31

Q42188852-6573873B-1BC3-4FE5-80B5-B697A9594998

P356

Q42188852-90A4B48F-92AF-43DC-8C7E-F21B17F6B999

P433

Q42188852-B1D5DB74-812A-4E3F-9FBE-EF1ACD5E1015

P478

Q42188852-0211C0F8-E7ED-4196-BAE2-CE71081A2997

P577

Q42188852-9B163F46-BE80-4936-B8CE-B154A6DCE574

P698

Q42188852-5467ED4A-CAFC-456D-AB21-877F695C40F3

P356

P1433

American Journal of Nephrology

P1476

Foscarnet nephrotoxicity: mechanism, incidence and prevention.

@en

P2093

Baumelou A

http://www.w3.org/2001/XMLSchema#string

Beaufils H

http://www.w3.org/2001/XMLSchema#string

Danis M

http://www.w3.org/2001/XMLSchema#string

Deray G

http://www.w3.org/2001/XMLSchema#string

Dohin E

http://www.w3.org/2001/XMLSchema#string

Gentilini M

http://www.w3.org/2001/XMLSchema#string

Katlama C

http://www.w3.org/2001/XMLSchema#string

Levaltier B

http://www.w3.org/2001/XMLSchema#string

Martinez F

http://www.w3.org/2001/XMLSchema#string

Rozenheim M

http://www.w3.org/2001/XMLSchema#string

P304

316-321

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000167987

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

1989-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

2554731

http://www.w3.org/2001/XMLSchema#string